Be Biopharma IPO

Be Biopharma (“Be Bio”) is pioneering Engineered B Cell Medicines (BeCM) to dramatically improve patients’ lives who are living with cancer, rare diseases and other serious conditions. The company's medicines address major hurdles of cell and gene therapies, and are durable, re-disable, and can be administered without toxic conditioning, thereby enabling healthcare sectors and patients to treat diseases like cancer, autoimmune conditions, and an enzyme deficiency. Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity. Be Bio was founded in October 2020 by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D. from Seattle Children’s Research Institute.

Register for Details

For more details on financing and valuation for Be Biopharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Be Biopharma's ticker symbol?

Be Biopharma does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

What is Be Biopharma's stock price?

The stock price for Be Biopharma will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Who are Be Biopharma's major investors?

Atlas Venture
Ra Capital Management
Longwood Fund
Alta Partners
Takeda Ventures
Arch Venture Partners
Bristol Myers Squibb

Be Biopharma Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
4/14/2022 Series B $280.11MM $XXX.XX $XXX.XX
10/22/2020 Series A $91.57MM $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Be Biopharma

Forge green plus iconForge green minus icon

What is Be Biopharma funding to date?

Be Biopharma has raised $182.1MM with the following series:
$91.57MM for Series A, $280.11MM for Series B, $91.57MM for Series A, $280.11MM for Series B.
Forge green plus iconForge green minus icon

When was Be Biopharma founded?

Be Biopharma was founded in 2020.
Forge green plus iconForge green minus icon

Can you invest in Be Biopharma?

Be Biopharma is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Be Biopharma share pre-IPO?

If you own Be Biopharma pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Be Biopharma a publicly traded company?

Be Biopharma is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Other companies like Be Biopharma in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation